20160620 CCMG-CSCC Poster Presentations: CCMG

Interactive session with the authors of poster presentations.

MG-200 The clinical utility of targeted next generation sequencing in prenatal congenital heart disease
Yanwei Xi, Alberta Children’s Hospital

MG-201 7p22.3p22.2 microdeletion is associated with variable developmental delay and characteristic facial features
Andrea Yu, Children’s Hospital of Eastern Ontario

MG-202 A new case of 5q31 microdeletion syndrome and putative causative genes
Caitlin Chang, Alberta Children’s Hospital

MG-203 ALG9-CDG: New Clinical Case and Review of the Literature
Kellie Davis, Alberta Children’s Hospital

MG-204 A rare four break balanced reciprocal insertional chromosomal translocation – a case report
Kathleen Bone, Alberta Children’s Hospital

MG-205 Novel WDR45 mutation identified in patient diagnosed with Beta-propeller protein associated neurodegeneration
Marisa Chard, University of Calgary

MG-206 Novel HPD mutations identified in First Nations Canadian siblings diagnosed with Tyrosinemia Type III
Alison Eaton, University of Calgary

Question Title

* 1. Please Rate Each Session:

	Did Not Attend	Poor	Fair	Good	Very Good	Excellent
MG-200 The clinical utility of targeted next generation sequencing in prenatal congenital heart disease	MG-200 The clinical utility of targeted next generation sequencing in prenatal congenital heart disease Did Not Attend	MG-200 The clinical utility of targeted next generation sequencing in prenatal congenital heart disease Poor	MG-200 The clinical utility of targeted next generation sequencing in prenatal congenital heart disease Fair	MG-200 The clinical utility of targeted next generation sequencing in prenatal congenital heart disease Good	MG-200 The clinical utility of targeted next generation sequencing in prenatal congenital heart disease Very Good	MG-200 The clinical utility of targeted next generation sequencing in prenatal congenital heart disease Excellent
MG-201 7p22.3p22.2 microdeletion is associated with variable developmental delay and characteristic facial features	MG-201 7p22.3p22.2 microdeletion is associated with variable developmental delay and characteristic facial features Did Not Attend	MG-201 7p22.3p22.2 microdeletion is associated with variable developmental delay and characteristic facial features Poor	MG-201 7p22.3p22.2 microdeletion is associated with variable developmental delay and characteristic facial features Fair	MG-201 7p22.3p22.2 microdeletion is associated with variable developmental delay and characteristic facial features Good	MG-201 7p22.3p22.2 microdeletion is associated with variable developmental delay and characteristic facial features Very Good	MG-201 7p22.3p22.2 microdeletion is associated with variable developmental delay and characteristic facial features Excellent
MG-202 A new case of 5q31 microdeletion syndrome and putative causative genes	MG-202 A new case of 5q31 microdeletion syndrome and putative causative genes Did Not Attend	MG-202 A new case of 5q31 microdeletion syndrome and putative causative genes Poor	MG-202 A new case of 5q31 microdeletion syndrome and putative causative genes Fair	MG-202 A new case of 5q31 microdeletion syndrome and putative causative genes Good	MG-202 A new case of 5q31 microdeletion syndrome and putative causative genes Very Good	MG-202 A new case of 5q31 microdeletion syndrome and putative causative genes Excellent
MG-203 ALG9-CDG: New Clinical Case and Review of the Literature	MG-203 ALG9-CDG: New Clinical Case and Review of the Literature Did Not Attend	MG-203 ALG9-CDG: New Clinical Case and Review of the Literature Poor	MG-203 ALG9-CDG: New Clinical Case and Review of the Literature Fair	MG-203 ALG9-CDG: New Clinical Case and Review of the Literature Good	MG-203 ALG9-CDG: New Clinical Case and Review of the Literature Very Good	MG-203 ALG9-CDG: New Clinical Case and Review of the Literature Excellent
MG-204 A rare four break balanced reciprocal insertional chromosomal translocation – a case report	MG-204 A rare four break balanced reciprocal insertional chromosomal translocation – a case report Did Not Attend	MG-204 A rare four break balanced reciprocal insertional chromosomal translocation – a case report Poor	MG-204 A rare four break balanced reciprocal insertional chromosomal translocation – a case report Fair	MG-204 A rare four break balanced reciprocal insertional chromosomal translocation – a case report Good	MG-204 A rare four break balanced reciprocal insertional chromosomal translocation – a case report Very Good	MG-204 A rare four break balanced reciprocal insertional chromosomal translocation – a case report Excellent
MG-205 Novel WDR45 mutation identified in patient diagnosed with Beta-propeller protein associated neurodegeneration	MG-205 Novel WDR45 mutation identified in patient diagnosed with Beta-propeller protein associated neurodegeneration Did Not Attend	MG-205 Novel WDR45 mutation identified in patient diagnosed with Beta-propeller protein associated neurodegeneration Poor	MG-205 Novel WDR45 mutation identified in patient diagnosed with Beta-propeller protein associated neurodegeneration Fair	MG-205 Novel WDR45 mutation identified in patient diagnosed with Beta-propeller protein associated neurodegeneration Good	MG-205 Novel WDR45 mutation identified in patient diagnosed with Beta-propeller protein associated neurodegeneration Very Good	MG-205 Novel WDR45 mutation identified in patient diagnosed with Beta-propeller protein associated neurodegeneration Excellent
MG-206 Novel HPD mutations identified in First Nations Canadian siblings diagnosed with Tyrosinemia Type III	MG-206 Novel HPD mutations identified in First Nations Canadian siblings diagnosed with Tyrosinemia Type III Did Not Attend	MG-206 Novel HPD mutations identified in First Nations Canadian siblings diagnosed with Tyrosinemia Type III Poor	MG-206 Novel HPD mutations identified in First Nations Canadian siblings diagnosed with Tyrosinemia Type III Fair	MG-206 Novel HPD mutations identified in First Nations Canadian siblings diagnosed with Tyrosinemia Type III Good	MG-206 Novel HPD mutations identified in First Nations Canadian siblings diagnosed with Tyrosinemia Type III Very Good	MG-206 Novel HPD mutations identified in First Nations Canadian siblings diagnosed with Tyrosinemia Type III Excellent

Question Title

* 2. Please assess the Sessions as a whole

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree
Sufficient time was allowed for audience participation/active learning	Sufficient time was allowed for audience participation/active learning Strongly Disagree	Sufficient time was allowed for audience participation/active learning Disagree	Sufficient time was allowed for audience participation/active learning Neutral	Sufficient time was allowed for audience participation/active learning Agree	Sufficient time was allowed for audience participation/active learning Strongly Agree
The facilities were satisfactory	The facilities were satisfactory Strongly Disagree	The facilities were satisfactory Disagree	The facilities were satisfactory Neutral	The facilities were satisfactory Agree	The facilities were satisfactory Strongly Agree
The session was free from commercial bias	The session was free from commercial bias Strongly Disagree	The session was free from commercial bias Disagree	The session was free from commercial bias Neutral	The session was free from commercial bias Agree	The session was free from commercial bias Strongly Agree
Overall, I would rate this Symposium as excellent	Overall, I would rate this Symposium as excellent Strongly Disagree	Overall, I would rate this Symposium as excellent Disagree	Overall, I would rate this Symposium as excellent Neutral	Overall, I would rate this Symposium as excellent Agree	Overall, I would rate this Symposium as excellent Strongly Agree

Question Title

* 3. As a result of attending these sessions, I am planning to:

a) Discuss the session with my colleagues

b) Pursue additional learning activities.

c) Complete a Personal Learning Project.

d) Not change my practice.

e) Change my practice.

Question Title

* 4. Please explain any changes you plan to make or personal learning projects you will pursue as a result of this session:

Question Title

* 5. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Medical Expert

Communicator

Collaborator

Manager

Health Advocate

Scholar

Professional

20160620 CCMG-CSCC Poster Presentations: CCMG

Interactive session with the authors of poster presentations.

Question Title

* 1. Please Rate Each Session:

Question Title

* 2. Please assess the Sessions as a whole

Question Title

* 3. As a result of attending these sessions, I am planning to:

Question Title

* 4. Please explain any changes you plan to make or personal learning projects you will pursue as a result of this session:

Question Title

* 5. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Question Title

* 6. General comments about individual speakers:

Question Title

* 7. What topics would you like to be addressed at future conferences to keep you up to date in your profession?